UK-500,001

TERMINATED · PHASE2 · Pulmonary Disease, Chronic Obstructive

The decision to terminate was completely related to efficacy and there were no safety concerns.

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.